Launch Therapeutics

Launch Therapeutics is a biotech and biopharma solutions provider fully dedicated to late-stage innovation. The company offers a range of tailored collaboration models and expertise in regulatory strategy, clinical development, manufacturing, and commercialization. Backed by renowned investors The Carlyle Group and Abingworth, Launch Tx was established in 2022 with a mission to expedite the approval and delivery of therapies. The company's emphasis on connecting drug candidates with development funding and its vision of redefining late-stage development positions it poised for significant impact. With a focus on Biopharma, Biotechnology, and Clean Energy, Launch Tx's influence extends from its headquarters in the United States, evident in its recent Private Equity Round investment in partnership with industry giants, The Carlyle Group and Abingworth on 11th April 2022.